DAFNA Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

DAFNA Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-45,800	Closed	-$255K	–	92
2026 Q1	$255K	Sell	45,800 -5,200	-10%	-$39.6K	0.06%	81
2025 Q4	$375K	Buy	+51,000	New	+$312K	0.09%	72
2024 Q4	–	Sell	-12,845	Closed	-$160K	–	84
2024 Q3	$160K	Hold	12,845	–	–	0.04%	84
2024 Q2	$167K	Hold	12,845	–	–	0.04%	81
2024 Q1	$291K	Hold	12,845	–	–	0.07%	68
2023 Q4	$167K	Hold	12,845	–	–	0.04%	73
2023 Q3	$258K	Hold	12,845	–	–	0.08%	68
2023 Q2	$345K	Hold	12,845	–	–	0.09%	64
2023 Q1	$750K	Hold	12,845	–	–	0.22%	54
2022 Q4	$655K	Buy	+12,845	New	+$890K	0.18%	58

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

DAFNA Capital Management's KPTI Position: Q2 2026 in Review

DAFNA Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2026, closing a stake of 45,800 shares — an estimated $255K sold.

DAFNA Capital Management first reported a position in KPTI in Q4 2022 and held it in 10 quarters. The position peaked at $750K in Q1 2023. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

DAFNA Capital Management reported no remaining Karyopharm Therapeutics position as of Q2 2026 after selling out during the quarter.
DAFNA Capital Management sold 45,800 Karyopharm Therapeutics shares in Q2 2026, an estimated $255K.
DAFNA Capital Management first reported a position in Karyopharm Therapeutics in Q4 2022 and held it in 10 quarters.
DAFNA Capital Management's Karyopharm Therapeutics position peaked at $750K in Q1 2023.
97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.